M
alignant ascites is defined as abnormal accumulation of intraperitoneal fluid as a consequence of advanced cancer [1] [2] [3] . It is often refractory to medical therapies and is associated with a decline in patients' quality of life [1] [2] [3] . Management of malignant ascites is still a major unsolved problem in the palliative care of patients with cancer.
The causes of refractory (i.e., resistant to various medical treatments) ascites include dissemination of malignant tumor, portal hypertension, and obstruction of the inferior vena cava or portal vein. In patients with portal hypertension or mechanical venous obstruction, a transjugular intrahepatic portosystemic shunt (TIPS) or stent placement in the obstructed vein may be the treatment of choice for reducing production of ascites [4] [5] [6] . However, patients for whom these procedures are not appropriate or for whom these definitive treatments fail require palliative treatment, such as paracentesis or peri toneovenous shunt (PVS) [1, [7] [8] [9] .
OBJECTIVE. This multicenter phase I/II study evaluated the safety and the efficacy of transjugular transhepatic peritoneovenous shunt (PVS), a new palliative treatment for malignant refractory ascites.
SUBJECTS AND METHODS.
Patients with refractory malignant ascites and patent hepatic veins and vena cava were included in this study. Eligible patients underwent the placement of transjugular transhepatic PVS catheter via the jugular vein into the abdominal cavity through the hepatic vein. In phase I, a step-by-step analysis of the safety was performed. The safety and the efficacy were determined through phases I and II.
RESULTS. Thirty-three patients were entered in this study, nine in phase I and 24 in phase II. Transjugular transhepatic PVS was technically successful in all patients. No severe adverse events were observed during the placement procedure. After the placement, 22 adverse events (grade 2 or higher) occurred. Frequent adverse events were hypoalbuminemia (24%) and decrease in hemoglobin (18%), which resolved within 1 week without additional treatment. The clinical efficacy rate at 1 week after the procedure was 67%. Occlusion of the catheter due to fibrin sheath was observed in seven patients, and the revision of the system was performed.
CONCLUSION. Transjugular transhepatic PVS is a safe and feasible procedure for managing refractory ascites in patients with cancer. Sufficient efficacy was observed in our initial experience, but a larger clinical trial is warranted. 
Subjects and Methods

Study Design
This study is a prospective multiinstitutional single-arm noncomparative phase I/II study for evaluating the safety and efficacy of transjugular transhepatic PVS for the treatment of malignant refractory ascites. The study design of the phase I portion consisted of the JIVROSG 3 × 3 method, which has been described in detail elsewhere [15] . In brief, this is a step-by-step safety evaluation in the first nine patients: a cohort of three patients is treated with transjugular transhepatic PVS, and if no severe adverse events occur during the observation period of 4 weeks, the next cohort of three patients is treated followed by the next observation period, and finally the third cohort of three patients is treated. The phase II portion was designed to enroll an additional 24 patients. To determine study outcomes, all enrolled patients were included in the intention-to-treat analysis.
Patients
Patients with refractory malignant ascites interfering with their daily life were eligible for participation in this study. Additional inclusion criteria were as follows: clear and serous ascites; patent hepatic veins and vena cava on contrast-enhanced CT; Eastern Cooperative Oncology Group performance status of 0-3; adequate organ function as defined by a hemoglobin level of 8.0 g/dL or higher, WBC count of 3000/mm 3 /dL or higher, platelet count of 50,000/mm 3 /dL or higher, prothrombin time of 50% or more, bilirubin level of 2.0 mg/dL or lower, serum creatinine level of 2.0 mg/dL or lower, normal ECG, PaO 2 level 70 mm Hg or higher at room air; and a life expectancy of at least 4 weeks. Exclusion criteria were as follows: manageable ascites with standard anticancer treatments; planned intraperitoneal drug administration; ascites caused by liver cirrhosis, mesothelioma, pseudomyxoma, or mucin-producing tumors; hemorrhagic or chylous ascites; active infectious disease; varices or ulcers in upper gastrointestinal tract; a history of hepatectomy; implanted cardiac pacemaker; or pregnant or nursing.
The study protocol was approved by the institutional review board at each institution before patient enrollment. Written informed consent was obtained from all patients. This study is registered under Clinical Trials Registry number C000000040 (www.umin.ac.jp/ctr/index.htm).
Technique of Transjugular Transhepatic PVS
Transjugular transhepatic PVS procedures were performed using a dedicated transjugular transhepatic PVS catheter and a TIPS system (Rösch-Uchida Transjugular Liver Access Kit, Cook Medical). The transjugular transhepatic PVS catheter is a urethane catheter with a hydrophilic coating, 8.2-French in diameter and 120 cm in length, accommodating a 0.035-or 0.038-inch guidewire at the tapered tip ( Fig. 1 ). It has a tapered 5-French pigtail-shaped tip, five side holes along the 8.2-French section 14-40 cm from the tip, and a one-way valve located 70-80 cm from the tip. We designed a tapered pigtail catheter to soften its tip so as to avoid injury to the abdominal organs. The diameter of the section containing the valve is 10-French. The pressure-activated one-way valve opens when the internal pressure is greater than 2 cm H 2 O pressure, thus allowing fluid to flow one way from the abdominal cavity to the vein.
Prophylactic IV antibiotics were administered just before the procedure. Each patient underwent conscious sedation with analgesics, and sedatives were administered according to individual needs. The patient was placed in the supine position on an angiography table. After administration of local anesthesia, the internal jugular vein was punctured under ultrasound guidance and an 11-French hemostatic sheath was placed into the inferior vena cava. A 5-French selective angiographic catheter was inserted through the sheath into a peripheral branch of the hepatic vein, and digital subtraction angiography was performed to confirm the shape of the hepatic vein and the position of the catheter tip. The 11-French sheath was advanced deeper into the hepatic vein by the overthe-wire technique. The choice of hepatic venous branch depended on its shape to fit the curve of the Rösch-Uchida needle of TIPS system. An inner catheter of the TIPS system was inserted into the tip of the sheath, and a Rösch-Uchida needle with a 5-French catheter was passed through the liver parenchyma to access the abdominal cavity. A stiff 0.035-inch Amplatz guidewire (Cook Medical) was inserted into the abdominal cavity through the catheter connecting to the abdominal cavity. The 11-French hemostatic sheath without a curved guiding cannula was advanced to the abdominal cavity, and the backward flow of ascites from the sheath was confirmed.
Subsequently, a transjugular transhepatic PVS catheter was inserted into the abdominal cavity through the 11-French hemostatic sheath, and then the sheath and guidewire were removed. The position of the transjugular transhepatic PVS catheter 
Transjugular Transhepatic Peritoneovenous Shunt
was adjusted so that the tip and side holes were in ascites, and the one-way valve was in the superior vena cava. After the backward flow of ascites from the transjugular transhepatic PVS catheter was confirmed and the position of the transjugular transhepatic PVS catheter was verified by fluoroscopy, the catheter was sutured to the skin of the neck. The external section of the catheter was cut at 2-3 cm from the insertion site and capped with a small silicone cap. We did not totally implant the proximal tip of the catheter subcutaneously because we assumed that adverse events resulting from implanted proximal tip, such as bleeding or infection, might be considerable and confound the safety assessment of the "transhepatic" PVS, which is unique for the transjugular transhepatic PVS. The position of the catheter was recorded by radiography (Fig. 2) . Abdominal and central venous pressure were measured and recorded during the procedure.
After the procedure was completed, vital signs of the patient were monitored, and continuous IV low-dose catecholamine was administered until the next day. Monitoring and catecholamine administration were terminated on the day following the procedure if there were no problems.
Safety and Efficacy Evaluation
The primary endpoint through the phase I to phase II portion was to characterize the safety of transjugular transhepatic PVS within a 4-week period after the procedure. Adverse events were evaluated using National Cancer Institute Common Toxicity Criteria (version 2.0) [16] , which were the standard criteria for evaluating cancer treatments at the time of initiation of this study.
Secondary endpoints were the rate of technical success of the procedure and clinical efficacy. Clinical efficacy was evaluated at 1 week after the procedure and was followed up until death or the time of termination of the study. Because established standard criteria for symptom evaluation for ascites did not exist, we defined the efficacy criteria (Table 1) .
Statistical Methods
This study was designed to detect the incidence of adverse events, which was the primary endpoint. The required number of patients was calculated to be 33, which included a dropout rate of 10%, and was based on the following variables: α, 0.05; power, 0.8; unacceptable rate of adverse events, 30%; estimated lowest rate of adverse events, 10%; and predicted rate of adverse events, 10%. Statistical analyses for patient demographics and adverse events were descriptive. The statistical significance level was set at 0.05 using a two-sided test. All statistical analyses were performed with PASW software (version 18, SPSS).
Results
Patient Characteristics and Follow-Up Period
There were 33 eligible patients enrolled between February 2003 and April 2007 from seven tertiary centers in Japan. All patients underwent transjugular transhepatic PVS and were evaluable for the primary endpoint of adverse events. Patient characteristics are summarized in Table 2 . The median follow-up period was 34 days (range, 8-144 days). Eight patients died within 30 days after undergoing the transjugular transhepatic PVS procedure. In all subjects, the cause of deaths was judged to be disease progression, and the judgments were approved by the safety and efficacy evaluation committee, which is independent from this clinical trial group.
Results of Procedures
The transjugular transhepatic PVS catheter was successfully implanted in all patients. The access site was the right internal jugular vein in 28 patients (85%) and the left internal jugular vein in five patients (15%). Peritoneal access was established through the right hepatic vein in 32 patients (97%) and the middle hepatic vein in one patient (3%). The mean (± SD) pressure gradient between the abdominal cavity and central vein was 17 ± 6 cm H 2 O. The duration of the procedure was 53 ± 30 minutes. Table 3 lists the observed adverse events of grade 2 or higher that were considered possibly, probably, or definitely related to the transjugu- 
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lar transhepatic PVS procedure. Overall, the transjugular transhepatic PVS procedure was well tolerated, with no severe adverse events encountered during the implantation. The most frequent adverse events were hypoalbuminemia (24%) and decrease in hemoglobin (18%), both of which occurred within 1-2 days after the procedure and resolved within 1 week. No grade 4 adverse events were encountered. No bleeding event related to the penetration of hepatic parenchyma was observed, and disseminated intravascular coagulation syndrome did not occur in any of the patients.
Clinical Efficacy
The efficacy of transjugular transhepatic PVS is summarized in Table 4 . The clinical efficacy rate (significantly effective or moderately effective) 1 week after the procedure was 67%. In seven patients for whom the procedure was initially effective (significantly or moderately effective), an increase in ascites volume and progression of subjective symptoms was again observed 19-51 days (median, 25 days) after the transjugular transhepatic PVS procedure. The cause of the reincrease in ascites was catheter dysfunction in all seven patients. Catheter dysfunction was caused by fibrin sheath formation around the one-way valve in all patients, which was confirmed by angiography via the transjugular transhepatic PVS catheter (Fig.  3) . Subsequently, additional treatments, such as catheter exchange or stripping of the fibrin sheath using a catheter and a guidewire, were undertaken. These procedures corrected the malfunctioning catheter in all patients; however, in five patients, reocclusion occurred within 10 days.
Discussion
This phase I/II study was performed as the initial step in the evaluation of transjugular transhepatic PVS. The JIVROSG 3 × 3 method, which was developed and validated in previous studies [15] by our group, was used for the phase I portion of this study. Because the concept of "dose escalation" in a phase I drug study is not applicable, the same transjugular transhepatic PVS intervention was performed throughout the study, and clinical efficacy was evaluated in all enrolled patients.
The inclusion criteria of this study were established according to the indications for the Denver shunt. In addition, patency of the vena cava, no history of cardiac pacemaker, no history of hepatic lobectomy, and no dilated intestine were included to secure a safe access route for transjugular transhepatic PVS. The exclusion criteria (i.e., cirrhosis and high risk for gastrointestinal bleeding) were added because of previous reports of severe adverse events resulting from PVS placement in cirrhotic patients [7, 11, 17, 18] . Won and coworkers [7] reported that 63% of 55 patients with refractory ascites developed variceal bleeding after Denver shunt placement. The characteristics of patients in this study, such as primary tumor, age, performance status, and the use of diuretics, may be consistent with typical patients with malignant refractory ascites.
For most of our study patients, the access site and the hepatic vein penetration site were the right internal jugular vein and the right hepatic vein, respectively, most likely because of the familiarity with right internal jugular access and the selection of the right hepatic vein resulting from experience with TIPS placement or other interventional procedures. In a few patients, however, the left internal jugular vein and middle or left hepatic vein were used, and the feasibility of these access sites was shown. Technical success was achieved in all patients from seven participating institutions, and the procedure time was approximately 1 hour. Thus, this technique is presumed to be feasible and can be generalized.
Concerning the safety of transjugular transhepatic PVS, it is significant that eight patients died within 30 days after transjugular transhepatic PVS placement, because patients considered to have 4 or more weeks Skin irritation at the access site 3 0 0 3
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Congestive heart failure 0 1 0 1 Transjugular Transhepatic Peritoneovenous Shunt of life expectancy were enrolled. However, previous reports on PVS have also described early patient deaths independent from the procedure [1-3, 19, 20] . Thus, this phenomenon can be understood as a general tendency in patients with malignant refractory ascites who are candidates for PVS. Decreases in serum albumin and hemoglobin have been reported in previous studies of PVS and were explained as the results of transient dilution caused by the inflow of ascites into the blood circulation [3] . Transient pleural effusion and congestive heart failure have also been reported as adverse events after PVS and could be also explained by the increased blood volume caused by the inflow of ascites. Thus, these adverse events in our study are not thought to be specific to transjugular transhepatic PVS but to be the general results of PVS. Skin inflammation around the transjugular transhepatic PVS catheter insertion site was an adverse event unique to this procedure, although it was not a severe adverse event. Bleeding events related to the penetration of hepatic parenchyma, which was considered as an adverse event specific to transjugular transhepatic PVS, were not observed. Therefore, on the basis of these safety results, the transjugular transhepatic PVS procedure is thought to be sufficiently safe to apply future clinical usage and evaluation. Concerning efficacy, 67% of patients achieved symptomatic improvement (significantly effective or moderately effective). The efficacy of PVS in previous studies is controversial because the evaluation criteria, including objective findings, varied and the comparability was uncertain [1, 3] . Given that the goal of this treatment is to palliate subjective symptoms, precise and consistent evaluation of the efficacy of transjugular transhepatic PVS in comparison with previous reports of PVS is impossible. However, in most of the previous reports, efficacy rates based on the improvement of symptoms were approximately 70%. Therefore, the efficacy of transjugular transhepatic PVS with regard to symptom improvement is equivalent to that in previous reports of other types of PVS.
The reason for fibrin sheath formation in seven of the 22 patients in whom the procedure was judged as significantly effective or moderately effective may be that the intravascular catheter used in transjugular transhepatic PVS is longer than the intravascular catheters used in other types of PVS or that the transjugular transhepatic PVS catheter has a one-way valve in the central vein. If these explanations are correct, they are intrinsic drawbacks of transjugular transhepatic PVS and cannot be avoided. However, no increase in ascites was seen in the other 15 patients. There have also been quite a few reports of fibrin sheath formation in previous PVS procedures [21] . The device of transjugular transhepatic PVS is developing and can be improved. Thus, the efficacy of transjugular transhepatic PVS should not be denied on the basis of this rate of fibrin sheath formation. In cases of fibrin sheath formation, exchanging the transjugular transhepatic PVS catheter is much easier compared with exchanging catheters of other implanted shunt systems, such as Denver shunts. This attribute seems to be a great advantage of transjugular transhepatic PVS. Nevertheless, improvement of the device may be the key for better clinical outcome in transjugular transhepatic PVS, particularly in the surface of the catheter where the fibrin sheath is formed. Antithrombogenic coating on the catheter would be one of the solutions. Other possibilities for refining the transjugular transhepatic PVS system include improvement of the function of the one-way valve and enlargement of the inner diameter of the catheter.
The following study limitations should be noted. The first is that the sample size was limited to 33 patients. Thus, there is a possibility that uncommon adverse events of transjugular transhepatic PVS were not detected. The second limitation is that this study was a single-arm and noncomparative study. Although the reported clinical efficacy of Denver PVS is 77.95% according to a systematic review by Becker et al. [1] , which is higher than our results of 67%, we cannot determine the superiority in efficacy without direct comparison by randomized controlled trial.
With this clinical trial, we conclude that the newly developed transjugular transhepatic PVS is feasible and a safe procedure for managing refractory ascites in patients with cancer, and transjugular transhepatic PVS has sufficient efficacy to be evaluated by a larger clinical trial in the future. In addition, improvement of the transjugular transhepatic PVS catheter is needed to reduce fibrin sheath formation and to obtain better clinical outcomes. 
